outperform price
debat own safe suppli player vs
evrisi thesi updat bdx print came well ahead
expect thought lsd organ print
impress consid legaci bcr intervent
portfolio grew addit minim
contribut covid dx bd grew despit net
covid headwind bp segment perspect
strength commentari around vaccin
inject opportun suggest upsid
round thought revenue declin could dd
low teen rang base april declin assumpt
around sequenti improv contribut increas
demand alari pump gener in-line
expect better worst case flip side alari
fda file expect slip recal push-out
capit sale hw also decrement
margin wors expect
put dent ep understand investor concern
around earn power believ tempor issu
like get pass investor believ
perceiv safeti natur suppli compani like
import caus us reaffirm outperform
rate pt equat price-to-earnings
ev/ebitda similar multipl
c/c
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
expect capit spend
nt pressur margin due high fix cost structur busi
gm rate higher compani average due impact lost rev
distribut center critic product oper near full capac
ramp product critical-to-covid devic
experienc histor high demand iv extens set specimen collect swab feb
expect june bd max reagent use open assay test assay kit inc output b/w
feb june
prepar capac address demand flu test antigen assay
reduc product lower-demand product tie elect procedur non-covid research
signific declin elect procedur
declin demand research reagent instrument
molecular pcr real-tim pcr test bd confirm activ infect hour
develop fourth point care antigen test
point-of-car test bd confirm activ infect littl min
serolog test detect igm igg antibodi littl min
help set field hospit ensur medic technolog locat
increas demand pyxi rapid emerg deploy offer deploy instal week
vascular access devic target temperatur management devic acut dialysi cathet
 exist alari custom receiv addit pump upon certif medic necess
emea manufactur custom shipment infus pump emea acceler
distribut agreement w/countri europ
on-going discuss w/ countri product syring potenti larg scale vaccin campaign
alreadi ramp product inject devic
conserv measur wc initi focu inventori management lower capital-expenditure reduc salari execut
board member got rid compani match benefit plan program remaind year
temporarili furlough small employe limit hire critic posit
expect recoveri
china seen recoveri europ lag monitor china recoveri see expect
pace defer procedur return normal biggest variabl
survey top account custom want begin resum elect earli june question
patient readi return
expect see biggest unfavor impact surgeri pi busi
mb ucc busi watch shift care non-acut set
diagnost expect see strong growth bd instrument assay use covid test
bioscienc busi depend research lab institut reopen quickli resum normal
oper capit spend
surgeri pi declin procedur impact surgeri rev intervent rev
surgeri still pre-covid expect china surgic intervent rev
europ
increas demand infus pump medic necess expect continu pace move
net tw
partial off-set continu delay pyxi instal expect continu
md continu see reduc demand acut non-acut busi
april rev pre-covid expect
combin declin april md
china hospit vol return bit april rev still pre-covid expect
europ continu covid surg demand rev pre-covid expect
ucc saw declin relat foley cathet demand april
diagnost preanalyt system fewer specimen collect lower non-covid test result
revenue declin april
expect meaning delay larg capit instal kiestra
bioscienc saw declin april due lab closur
estim neg impact due covid april
rev fxn covid impact bp
continu strong cadenc deliv pipelin
introduc new product
alari pend order volume medic necess high end march
order fill end rev record april
demand continu lesser april
extend time submit alari file
high demand insulin pen needl syring distributor retail inc inventori result
acceler distribut agreement innov new infus pump platform tailor european market
advanc presenc region
see strong demand offer diagnost deferr routin care led temporarili lower
lab closur immedi signific impact demand bioscienc reagent research instrument
use sampl collect devic
recoveri take time
launch symphoni system self-sort w/ sort panel detect
bd system continu exceed expect instal even
acquir diagnost compani w/ platform molecular point care market
elect procedur signific impact surgeri pi
oncolog end-stag renal diseas procedur least impact hernia peripher arteri diseas
biosurgeri busi impact
releas mm av low profil balloon see sequenti improv use drug coat balloon ex
close acquisit straub medic close
focu devic treat/restor blood flow clot block vessel
 europ
net tw europ
driven inc demand critic healthcar devic initi use bd max covid test partial
off-set declin non-acut area
major covid hw china
driven strict stay-at-hom measur result lower hospit util declin elect procedur
fewer routin lab test specimen collect reduc demand research lab
ad term loan
expect debt paydown year exclud term loan
extend time-frame achiev gross leverag due near-term anticip pressur ebitda
increas credit facil
expect mm tw apr alari abat may june
saw region recoveri esp late april see ppl start screen prior schedul elect
covid poc test develop
start clinic test last week may week submit eua
manuf capac ramp target millions/week
manuf capac /mo right add capac
apr mid-teen mm ldd incl mm benefit
margin impact revenu loss
last wk apr enough chang elect procedur chang view may
medic life scienc see real differ
subset busi saw uptick england hernia procedur heavili reimburs outpt base pick
nice back end april
doubl sku ration past two month
cut capital-expenditure mp
priorit mission critic esp area necessari covid delay discretionari perman adj
billion syring needles/year us need work govern get bn syringes/mon
valuat methodolog base mix discount cash flow analysi rel valuat multipl
integr risk relat bcr transact potenti headwind corpor tax reform weak
articl articl
time dissemin may pm et
analyst luke sergott cindi ding lilli shahidi vijay kumar primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
